Quantcast
Home > Quotes > IMUC

ImmunoCellular Therapeutics, Ltd. Common Stock (IMUC) Quote & Summary Data

IMUC 
$0.2107
*  
0.0006
0.28%
Get IMUC Alerts
*Delayed - data as of Sep. 19, 2018 10:56 ET  -  Find a broker to begin trading IMUC now
Exchange:AMEX
Industry: Health Care
Community Rating:
View:    IMUC Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

1 Year Target
Today's High / Low
$ 0.2163 / $ 0.204
Share Volume
45,671
90 Day Avg. Daily Volume
277,753
Previous Close
$ 0.2113
52 Week High / Low
$ 0.55 / $ 0.17
Market Cap
8,835,701
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.4

Intraday Chart

Shares Traded

Share Volume:
45,671
90 Day Avg. Daily Volume:
277,753

Trading Range

The current last sale of $0.2107 is 23.94% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.2163 $ 0.55
 Low: $ 0.204 $ 0.17

Company Description (as filed with the SEC)

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of cancers. Immunotherapy is an emerging approach to treating cancer in which a patient's own immune system is stimulated to target tumor antigens, which the immune system uses to identify foreign bodies. While some other cancer immunotherapies target only a single cancer antigen, our technology can elicit an immune response against several antigens simultaneously. Our clinical stage cancer immunotherapy programs are also distinguished by the fact that they target cancer stem cells (CSCs), which are the primary drivers of tumor growth and disease recurrence. Review of Strategic Alternatives We expect to devote substantial time and resources to exploring strategic alternatives that our board of directors believes will maximize stockholder value.  ... More ...  


Risk Grade

Where does IMUC fit in the risk graph?


Risk Grade Scale

Consensus Recommendation

Analyst Info